Anti-Aging Glycoprotein AAGP™ Protects and Repairs

PROTOKINETIX INC. (PKTX: OTCBB)
VANCOUVER, BRITISH COLUMBIA, October 17, 2006

ProtoKinetix, Inc. is publishing a confidential letter from the lead scientists of ITTEC Stem, Inc. regarding their observations of additional properties of AAGP™. This letter reads as follows:

“A number of studies have clearly demonstrated the UV protective capacity of anti-aging glycoprotein AAGP. Indeed, under intense UV light exposures a survival advantage of between 20-40% has been repeatedly demonstrated in cell lines incubated with AAGP while being simultaneously exposed to UV light. Interestingly, the latest exposure experiments suggest that AAGP may not only be protecting cells from UV light but may also be acting at a molecular level to possibly induce repair of damaged cells.

Some of the most recent data includes 1) cell lines exposed to UV light in the presence of AAGP but with AAGP removed immediately following UV exposure and 2) cell lines exposed to UV light with AAGP only added after the UV exposure. In both situations, the cells incubated with AAGP had a survival advantage similar as if AAGP had been added throughout and after the UV exposures. In addition to these results, an additional set of experiments demonstrated how even after 8 days following UV exposure and without changing the media throughout those 8 days, the only cells that were still viable were those that had been exposed to AAGP at one time point or another. Note that not changing the media in this experiment was done purposely so as to maintain a consistent environment resembling significant cell death and acidosis. The fact that cells survived in the AAGP treated cells (even when treated only after UV exposure) and that viability was maintained even after the harsh cellular conditions suggests AAGP may be acting at the molecular level (as a signalling molecule) to protect and potentially repair cells or promote their survival. The therapeutic benefits of such a protection/repair mechanism could potentially be of marked use in cases of myocardial infarction and stroke amongst other pathologies.”

- Sammer Hussein and Michael Palumbo. ITTEC Stem, Inc.

About ProtoKinetix:
ProtoKinetix Inc is a Biotechnical Company dedicated to the development of a family of synthetic antifreeze glycoproteins (AAGP™) for human and veterinary medicine, the bio technology and cosmetic industries. Using previously published research on native antifreeze proteins and antifreeze glycoproteins as a guide, and coordinating a vast pool of world recognized intellectual talent in a networked environment, PKTX is conducting rapid and meaningful research with a view to developing markets for this very useful family of molecules. Sign up for free automatic email news alerts at our new website at: www.protokinetix.com

The Private Securities Litigation  Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

On behalf of the Board of Directors

Dr. John Todd – President

Company Office:                                                           
Suite # 1500 885 West Georgia Street
Vancouver, BC V6C 3E8

Investor Contact:
ProtoKinetix Inc.
Blair Henderson
604-687-9887